Epoch Investment Partners Inc. Has $73.57 Million Holdings in Halozyme Therapeutics, Inc. $HALO

Epoch Investment Partners Inc. increased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 113.4% during the first quarter, Holdings Channel reports. The fund owned 1,138,377 shares of the biopharmaceutical company’s stock after purchasing an additional 605,018 shares during the period. Epoch Investment Partners Inc.’s holdings in Halozyme Therapeutics were worth $73,573,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Larson Financial Group LLC raised its position in Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 343 shares during the last quarter. Measured Wealth Private Client Group LLC grew its holdings in shares of Halozyme Therapeutics by 51.5% during the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 124 shares during the last quarter. Harbour Investments Inc. grew its holdings in shares of Halozyme Therapeutics by 152.5% during the fourth quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 372 shares during the last quarter. Clearstead Advisors LLC increased its stake in shares of Halozyme Therapeutics by 64.8% in the fourth quarter. Clearstead Advisors LLC now owns 842 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 331 shares in the last quarter. Finally, Wexford Capital LP acquired a new stake in shares of Halozyme Therapeutics in the third quarter valued at $70,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CEO Helen Torley sold 20,000 shares of the stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $71.75, for a total value of $1,435,000.00. Following the sale, the chief executive officer directly owned 767,780 shares in the company, valued at $55,088,215. This trade represents a 2.54% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $75.00, for a total transaction of $547,800.00. Following the transaction, the director directly owned 14,462 shares in the company, valued at $1,084,650. The trade was a 33.56% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 74,102 shares of company stock worth $5,205,798. Insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Stock Performance

Shares of Halozyme Therapeutics stock opened at $81.93 on Friday. The firm has a fifty day moving average of $73.08 and a two-hundred day moving average of $70.58. The stock has a market capitalization of $9.72 billion, a price-to-earnings ratio of 29.47, a PEG ratio of 0.34 and a beta of 0.84. Halozyme Therapeutics, Inc. has a 52 week low of $57.67 and a 52 week high of $82.99. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The business had revenue of $376.71 million for the quarter, compared to analyst estimates of $358.60 million. During the same period last year, the company earned $1.11 EPS. The firm’s revenue was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, equities research analysts predict that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. Morgan Stanley lowered their price objective on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. UBS Group reiterated a “buy” rating and set a $90.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. HC Wainwright reissued a “buy” rating and set a $95.00 price target on shares of Halozyme Therapeutics in a research note on Tuesday. Finally, Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday. Eight analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $81.60.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.